>>>>...and, of course, RPRX is only an $80 million company. That's the key point from an investment standpoint. They are sitting on two relatively low-risk drugs with profiles that could make them the treatments of choice for their respective indications.<<<<<<
RPRX is getting clipped...down 15% for value shoppers.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.